1609394-05-9Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS FOR INHIBITING TYK2 ACTIVITIES
-
Page/Page column 13, (2021/09/17)
Provided are Compounds 1-8, and their pharmaceutically acceptable salts or prodrugs thereof. Compounds 1-8 are selective binders to TYK2's JH2 and they exhibit significant inhibitory effects on the physiological function of TYK2 and they have excellent in vivo pharmacokinetic properties. Compounds 1-5 and 7 have several deuterium substitutions on methyl to improve pharmacokinetic (PK) properties.
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00424; 00426-00427, (2020/06/10)
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Wrobleski, Stephen T.,Moslin, Ryan,Lin, Shuqun,Zhang, Yanlei,Spergel, Steven,Kempson, James,Tokarski, John S.,Strnad, Joann,Zupa-Fernandez, Adriana,Cheng, Lihong,Shuster, David,Gillooly, Kathleen,Yang, Xiaoxia,Heimrich, Elizabeth,McIntyre, Kim W.,Chaudhry, Charu,Khan, Javed,Ruzanov, Max,Tredup, Jeffrey,Mulligan, Dawn,Xie, Dianlin,Sun, Huadong,Huang, Christine,D'Arienzo, Celia,Aranibar, Nelly,Chiney, Manoj,Chimalakonda, Anjaneya,Pitts, William J.,Lombardo, Louis,Carter, Percy H.,Burke, James R.,Weinstein, David S.
, p. 8973 - 8995 (2019/11/14)
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formi
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 001348; 001349, (2018/05/15)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES
-
Page/Page column 75; 76, (2017/09/02)
Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES
-
, (2014/05/24)
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES
-
Paragraph 00225; 00226, (2014/05/24)
Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
